

Long noncoding RNA HOXA-AS2 acts as an oncogene by targeting miR-145-3p in human non-small cell lung cancer

Y.-B. SHI¹, S.-L. LIU¹, X.-R. MOU¹, J. LIAO¹, J.-P. CHE¹, X.-Q. FEI¹, Y.-R. WANG²

¹Department of Cardiothoracic Surgery, Yantai Mountain Hospital, Yantai, China

²Department of Respiratory Medicine, Yantai Mountain Hospital, Yantai, China

Abstract. – OBJECTIVE: Recent studies have proved that long non-coding RNAs (lncRNAs) play important roles in many diseases, especially malignancies. The aim of this study was to investigate the exact role of lncRNA HOXA-AS2 (Hoxa cluster antisense RNA 2) in the development of non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was utilized to detect HOXA-AS2 expression in NSCLC patients. The Wound healing assay and transwell assay were conducted to explore the function of HOXA-AS2 on NSCLC metastasis. Furthermore, the mechanism assays were used to explore the interaction between HOXA-AS2 and microRNA-145-3p (miR-145-3p).

RESULTS: HOXA-AS2 expression level in NSCLC tissues was significantly higher than adjacent tissues. HOXA-AS2 expression was negatively correlated with disease-free survival of NSCLC patients. Moreover, the functional assays showed that the migration and invasion of NSCLC cells were significantly inhibited after HOXA-AS2 *in vitro* silence. Furthermore, the luciferase reporter assay also revealed that miR-145-3p was a direct target of HOXA-AS2 in NSCLC.

CONCLUSIONS: Our results indicated that HOXA-AS2 could enhance migration and invasion abilities of NSCLC by targeting miR-145-3p. Furthermore, these findings suggested that HOXA-AS2 might be a potential therapeutic target for NSCLC.

Key Words: Long non-coding RNA, HOXA-AS2, Non-small cell lung cancer (NSCLC), miR-145-3p.

Introduction

Lung cancer is one of the most frequent cancers in the world, both in terms of incidence and

mortality. Meanwhile, it remains a public threat to the society¹. Approximately 234,030 cases are diagnosed with lung cancer worldwide in 2018². Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases. The surgical resection is the main intervention for NSCLC patients diagnosed in early stages. Currently, tremendous advances have been made in the therapeutic treatment of NSCLC. However, the 5-year survival rate of NSCLC patients is still lower than 15%. Therefore, it is crucial to understand the molecular mechanism of NSCLC and find out new biomarkers for NSCLC treatment. About 90% of the mammalian genome is transcribed to non-coding ribonucleic acids (RNAs). Long non-coding RNAs (lncRNAs) are defined as non-coding RNAs with longer than 200 nucleotides in length. Recent studies have uncovered that lncRNAs are a new frontier field in the research of malignant diseases. For instance, lncRNA UCA1 accelerates the proliferation and cisplatin resistance in oral squamous cell carcinoma by modulating SF1 and suppressing miR-184³. In addition, activated by zinc finger E-box binding homeobox 1 (ZEB1), lncRNA HCCL5 accelerates the viability, migration, epithelial-mesenchymal transition (EMT), and malignancy of hepatocellular carcinoma⁴. Furthermore, lncRNA ATB promotes the migration and invasion of glioma cells by activating astrocytes by suppressing the expression of microRNA-204-3p⁵.

Scholars have revealed that microRNA (miRNA) plays a crucial role in the regulation of various biological behaviors, including cell proliferation, apoptosis, and metastasis. Likewise, activated by K-Ras carcinogenic signal, miR-155 facilitates the proliferation of pancreatic cancer cells by regulating ROS stress⁶. By targeting FMNL2, miR-613 functions as a tumor suppress-

sor gene in the progression of colorectal cancer⁷. MiR-126 plays an important role in breast cancer by interacting with a variety of molecules. Meanwhile, it may help to interfere with the inhibition of breast cancer cell metastasis⁶. Through downregulation of transcription factor FOXO1, the over-expression of miRNA-370 promotes the proliferation of human prostate cancer⁸.

LncRNA HOXA-AS2 (Hoxa cluster antisense RNA 2) plays an important role in tumor development and metastasis. In this study, we aimed to investigate the function of lncRNA HOXA-AS2 in NSCLC, as well as the interaction between HOXA-AS2 and miR-145-3p.

Patients and Methods

Tissue Samples

Totally, 62 patients who underwent surgical resection at Yantai Mountain Hospital were enrolled in this research. Human NSCLC tissues and adjacent non-tumor tissues were obtained from patients during surgery. After surgical resection, all collected tissue samples were snap-frozen in liquid nitrogen immediately for use. No radiotherapy and chemotherapy treatment were performed in any patient before the surgery. This study was approved by the Research Ethics Committee of Yantai Mountain Hospital. Informed consents were gathered from all the patients before the study.

Cell Culture

The human NSCLC cell lines (A549, SPCA1, PC-9, and H1299) were immortalized human bronchial epithelial cells (16HBE) were bought from American Type Culture Collection (ATCC; Manassas, VA, USA). All cells were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640) medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Life Technologies, Gaithersburg, MD, USA).

Cell Transfection

Adenovirus carrying short-hairpin RNA (shRNA) targeting HOXA-AS2 (HOXA-AS2/shRNA) was synthesized by GenePharma (Shanghai, China) and inserted into shRNA expression vector pGPH1/Neo. Subsequently, HOXA-AS2/shRNA was transfected into A549 NSCLC cells according to the instructions of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).

RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Total RNA in tissues and cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Subsequently, the extracted RNA was reverse transcribed to complementary deoxyribonucleic acid (cDNA) through reverse transcription Kit (TaKaRa, Technology Co., Ltd., Dalian, China). The primers used in this study were as follows: HOXA-AS2 forward: 5'-CCCGTAGGAGGAGGAGTGA-3' reverse: 5'-TTTAGGCCGCGCAAGGTC-3' glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers forward: 5'-CCAAAGAGATGGG-GCAATGAGG-3' reverse: 5'-TGATGGCA-TGGACTGTGGTCA-3'. The thermal cycle was as follows: 30 s at 95°C, 35 s for 40 cycles at 95°C and 35 s at 60°C.

Wound Healing Assay

The cells were first transferred into 6-well plates (Corning, Corning, NY, USA) and cultured in RPMI-1640 medium overnight. After scratched with a plastic tip, the cells were cultured in serum-free RPMI-1640. Wound closure was viewed under microscope. Each assay was independently repeated three times.

Transwell Assay

For detecting the migration ability of transfected cells, 5×10^4 cells in 200 μ L serum-free RPMI-1640 were transformed to the upper chamber of an 8 μ m pore size insert (Millipore, Billerica, MA, USA). To detect the invasion ability of the transfected cells, 5×10^4 cells in 200 μ L serum-free RPMI-1640 were transferred to the upper chamber of an 8 μ m pore size insert (Millipore, Billerica, MA, USA) coated with 50 μ g Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). Meanwhile, the lower chamber was added with RPMI-1640 and FBS. 48 h later, the top surface of the chambers was wiped by a cotton swab. Then, the chambers were immersed for 10 min with pre-cooled methanol and stained with crystal violet for 30 min. Three fields were randomly selected to count the data for invasion membrane.

Luciferase Reporter Gene Assay

The 3'-Untranslated Region (3'-UTR) of HOXA-AS2 was cloned into the pGL3 vector (Promega, Madison, WI, USA) as wild-type (WT) 3'-UTR. Quick-change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) was used for site-di-

rected mutagenesis of the miR-145-3p binding site in HOXA-AS2 3'-UTR as mutant (MUT) 3'-UTR. Subsequently, they were transfected into NSCLC cells. The luciferase assay was detected by the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).

Xenograft Model

After HOXA-AS2 was silenced in A549 cells, the cells were replanted into NOD/SCID mice (6 weeks old). The tumor volume was calculated every 5 days as the formula (volume = length $\times$ width² $\times$ 1/2). After 4 weeks, the tumors were extracted and calculated. This experiment was approved by the Animal Ethics Committee of Yantai Mountain Hospital.

Statistical Analysis

The Statistical Product and Service Solutions (SPSS) 20.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analysis. The data were expressed as mean $\pm$ SD (Standard Deviation). The Student's *t*-test method and the Kaplan-Meier method were utilized when appropriate. $p < 0.05$ was considered statistically significant.

Results

HOXA-AS2 Expression Level in NSCLC Tissues and Cell Lines

We first detected HOXA-AS2 expression in 62 NSCLC patients' tissues and 4

lines via qRT-PCR. The results showed that the HOXA-AS2 expression in NSCLC tissues samples was remarkably higher than that of adjacent non-tumor tissues (Figure 1A). Similarly, the HOXA-AS2 expression in NSCLC cell lines was significantly higher than that of normal cells as well (Figure 1B). Subsequently, the patients were divided into two groups according to the median expression of HOXA-AS2, including the high HOXA-AS2 expression group and low HOXA-AS2 expression group. The Kaplan-Meier analysis showed that the disease-free survival of NSCLC patients in the high HOXA-AS2 expression group was significantly worse than that in the low HOXA-AS2 expression group (Figure 2).

Silence of HOXA-AS2 Suppressed Migration and Invasion of NSCLC Cells

In this study, the A549 NSCLC cell line was chosen for the silence of HOXA-AS2 *in vitro*. The transfection efficiency of HOXA-AS2 was verified by qRT-PCR (Figure 3A). The wound healing assay showed that the silence of HOXA-AS2 significantly inhibited the migrated ability of A549 cells (Figure 3B). The transwell assay revealed that the number of migrated cells remarkably decreased after the HOXA-AS2 silence in A549 cells (Figure 3C). Moreover, the transwell assay revealed that the number of invaded cells was significantly reduced after HOXA-AS2 was silenced in the A549 cells as well (Figure 3D).




Figure 1. HOXA-AS2 was highly expressed in NSCLC tissues and cell lines. **A**, HOXA-AS2 expression significantly increased in NSCLC tissues compared with adjacent tissues. **B**, The expression levels of HOXA-AS2 relative to GAPDH were determined in human NSCLC cell lines and normal human bronchial epithelial cell 16HBE by qRT-PCR. The data were presented as mean $\pm$ standard error of the mean. * $p < 0.05$.




Figure 2. The association between HOXA-AS2 expression and NSCLC patients' prognosis. Higher expression of HOXA-AS2 was associated with worse disease-free survival of NSCLC patients.

Silence of HOXA-AS2 Suppressed Tumor Formation In Vivo

To detect the ability of HOXA-AS2 *in vivo*, the tumor formation assay was conducted in BALB/c nude/SCID mice. The results showed that the tumor size in HOXA-AS2/shRNA group was significantly less than that of the control group (Figure 4A). Four weeks later, the tumors were extracted from treated mice, and HOXA-AS2 expression in tumor tissues was detected by qPCR. As a result, HOXA-AS2 was significantly down-regulated in HOXA-AS2/shRNA group when compared with the control group (Figure 4B).

The Interaction Between MiR-145-3p and HOXA-AS2 in NSCLC

The bioinformatics software (DIANA LncBASE v2.0) was used to predict the miRNAs containing a complementary base with HOXA-AS2. miR-145-3p has been identified as a tumor suppressor in tumor metastasis. Therefore, miR-145-3p was selected from those predicted miRNAs. The predicted binding area of HOXA-AS2 is shown in Figure 5A. The subsequent results demonstrated that miR-145-3p was significantly up-regulated in HOXA-AS2/shRNA group than that of control cells (Figure 5B). The Luciferase Reporter Gene Assay revealed that the transfection of HOXA-AS2-WT and miR-145-3p significantly decreased the luciferase

activity (Figure 5C). Furthermore, the miR-145-3p expression level was negatively correlated with HOXA-AS2 expression in NSCLC tissues (Figure 5D).

Discussion

In the past several decades, the morbidity of lung cancer has increased worldwide, especially in industrially advanced countries. However, the main characteristics of NSCLC are migration and invasion of neoplasms, which are responsible for the high mortality rate. Previous studies have demonstrated that lncRNAs are important regulators in NSCLC progression. Up-regulated FGF1 by overexpression of lncRNA RAB1A-2 promotes NSCLC development, eventually leading to poor prognosis⁹. LncRNA PRNCR1 promotes the progression of NSCLC by up-regulating HEY2 through PRNCR1-miR-488-HEY2 network¹⁰.

HOXA-AS2, a cluster antisense RNA (2,100 bp) located on chromosome 6, plays vital roles in various processes. Authors^{11,12} have found that HOXA-AS2 participates in the development of cancers. Likewise, HOXA-AS2 facilitates breast cancer cell metastasis by targeting miR-520c-3p. HOXA-AS2 enhances cell growth ability by targeting P21 and KLF2 in colorectal cancer¹⁴. In this study, we found that HOXA-AS2 was significantly up-regulated in NSCLC tissues. Besides, the silence of HOXA-AS2 remarkably repressed the migration and invasion of NSCLC cells. The tumor formation assay also revealed that the silence of HOXA-AS2 could remarkably suppress tumor formation *in vivo*. All these results suggested that HOXA-AS2 acted as an oncogene and promoted tumor metastasis of NSCLC.

In this study, we further explored the possible mechanism of HOXA-AS2 function in NSCLC metastasis. Recent studies have shown that lncRNAs interact with microRNAs in malignant tumors. LncRNAs participate in the regulation of tumorigenesis by binding to the related regions of microRNAs as well. Indeed, the knockdown of lncRNA TUG1 depresses cell proliferation and invasion in osteosarcoma via sponging miR-153¹⁵. By interacting with miR-21-5p, lncRNA XIST represses the proliferation and metastasis of the osteosarcoma cells through regulation of PDCD4 expression¹⁶. LncRNA PVT1 promotes glucose metabolism, cell motility, cell proliferation, and tumor progression in osteosarcoma by modulating miR-497/HK2




Figure 3. The silence of HOXA-AS2 inhibits the NSCLC cell migration and invasion. **A**, HOXA-AS2 expression in A549 NSCLC cells transfected with HOXA-AS2/shRNA and control vector were detected by qRT-PCR. GAPDH was used as an internal control. **B**, The wound healing assay showed the silence of HOXA-AS2 significantly repressed the migration of A549 NSCLC cells (magnification: 10 $\times$). The transwell assay showed that the number of migrated cells significantly decreased after the silence of HOXA-AS2 in A549 NSCLC cells (magnification: 40 $\times$). **D**, The transwell assay showed that the number of invaded cells significantly decreased after the silence of HOXA-AS2 in A549 NSCLC cells (magnification: 40 $\times$). The results represented the average of three independent experiments (mean $\pm$ standard error of the mean). * $p < 0.05$, as compared with control cells.




Figure 4. Silence of HOXA-AS2 inhibited tumor formation *in vivo*. **A**, After tumor extraction, tumor volume was calculated respectively in control or HOXA-AS2/shRNA group and made into a graph. **B**, The relative expression of HOXA-AS2 in tumor was examined by qRT-PCR. Data were presented as mean $\pm$ SD of three independent experiments. * $p < 0.05$.




Figure 5. Reciprocal repression between HOXA-AS2 and miR-145-3p. **A**, The binding sites of miR-145-3p on HOXA-AS2. **B**, MiR-145-3p expression was significantly up-regulated in HOXA-AS2/shRNA group when compared with control group. **C**, Co-transfection of miR-145-3p and HOXA-AS2-WT significantly reduced luciferase activity. Co-transfection of miR-control and HOXA-AS2-WT did not change luciferase activity. Meanwhile, co-transfection of miR-145-3p and HOXA-AS2-MUT did not change luciferase activity either. **D**, The linear correlation between the expression level of miR-145-3p and HOXA-AS2 in NSCLC tissues. The results represented the average of three independent experiments. Data were presented as mean $\pm$ standard error of the mean. * $p < 0.05$.

axis¹⁷. By sponging miR-145-3p, lncRNA SNHG1 facilitates tumorigenesis of osteosarcoma through the regulation of NOB1.

The bioinformatics software was utilized to predict the potential target miRNAs of HOXA-AS2. MiR-145-3p was found to be overexpressed in many malignant tumors, including NSCLC. MiR-145-3p inhibits cell proliferation and induces apoptosis in osteosarcoma by regulating HIF1 α . UHRF1 regulated by miR-145-3p is associated with the progression of cell metastasis in bladder cancer. However, miR-145-3p is identified as a tumor suppressor gene in NSCLC^{21,22}. In this study, we firstly investigated the interaction between miR-145-3p and HOXA-AS2. The results demonstrated that miR-145-3p could bind to HOXA-AS2 *via* luciferase reporter gene assay. In addition, miR-145-3p expression was significantly suppressed by upregulated HOXA-AS2. Furthermore, the expression of miR-145-3p was negatively

correlated with HOXA-AS2 in NSCLC tissues. The above results indicated that HOXA-AS2 promoted tumor metastasis of NSCLC by targeting miR-145-3p.

Conclusions

These results showed that HOXA-AS2 was remarkably upregulated in NSCLC tissues and cells. HOXA-AS2 could facilitate the migration and invasion of NSCLC cells by targeting miR-145-3p. Meanwhile, our study first discovered the HOXA-AS2/miR-145-3p axis in NSCLC. Our findings might provide a candidate target for NSCLC treatment.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017; 67: 7-30.
- 2) HIRSCH FR, SCAGLIOTTI GV, MULSHINE JL, KWON R, CURRAN WJ, WU YL, PAZ-ARES L. Lung cancer: current therapies and new targeted treatments. *Lancet* 2017; 389: 299-311.
- 3) FANG Z, ZHAO J, XIE W, SUN Q, WANG H, QIAO B. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by suppressing miR-184 expression. *Cancer Med* 2017; 6: 2897-2908.
- 4) PENG L, JIANG B, YUAN X, QIU Y, PENG J, HUANG Y, ZHANG C, ZHANG Y, LIN Z, LI J, YAO W, DENG W, ZHANG Y, MENG M, PAN X, LI C, YIN D, BI X, LI G, LIN DC. Super-enhancer-associated long noncoding RNA HCCL5 is activated by ZEB1 and promotes the malignancy of hepatocellular carcinoma. *Cancer Res* 2019; 79: 572-584.
- 5) BIAN EB, CHEN EF, XU YD, YANG ZH, TANG F, MA CC, WANG HL, ZHAO B. Exosomal lncRNAATB activates astrocytes that promote glioma cell invasion. *Int J Oncol* 2019; 54: 713-721.
- 6) WANG P, ZHU CF, MA MZ, CHEN G, SONG M, ZENG ZL, LU WH, YANG J, WEN S, CHIAO PJ, HU Y, HUANG P. Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer. *Oncotarget* 2015; 6: 21148-21158.
- 7) LI B, XIE Z, LI Z, CHEN S, LI B. MicroRNA-612 targets FMNL2 and suppresses progression of colorectal cancer. *Am J Transl Res* 2016; 8: 5475-5484.
- 8) WU Z, SUN H, ZENG W, HE J, MAO X. Upregulation of microRNA-370 induces proliferation in human prostate cancer cells by regulating the transcription factor FOXO3. *Oncotarget* 2012; 7: e45825.
- 9) WU D, YANG B, CHEN J, LI H, LI Y, CHEN J, LI T, ZHOU S, JING Y, LIU Y, ZHOU Y, F, YANG L, LU J. Upregulation of long non-coding RNA RAB1A-2 induces FGF1 expression worsening lung cancer prognosis. *Cancer* 2018; 438: 116-125.
- 10) CHENG D, FANG Z, ZHANG L, LIN X, HUANG H, ZHAO L. LncRNA PTCR1 interacts with HEY2 to abolish miR-424-mediated growth inhibition in non-small cell lung cancer. *Biomed Pharmacother* 2018; 105: 140-154.
- 11) LIU Y, YU H, LIU Y, LIU X, ZHENG J, MA J, GONG W, LI J, ZHANG J, TIAN X, QIE Y. Long non-coding RNA HOXA-AS2 represses malignant glioma behavior and vascular mimicry formation via the miR-145/VEGFA Axis. *Cell Physiol Biochem* 2018; 45: 111-121.
- 12) XIE M, SUN M, ZHU YN, XIA R, LIU YW, DING J, MA HW, HE XZ, ZHANG ZH, LIU ZJ, LIU XH. Long noncoding RNA HOXA-AS2 promotes non-small cell lung cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression. *Oncotarget* 2015; 6: 33587-33601.
- 13) FANG Y, WANG J, WU F, SONG Y, ZHANG Q, ZHANG Q. Long non-coding RNA HOXA-AS2 promotes proliferation and invasion of breast cancer cells as a miR-520c-3p sponge. *Oncotarget* 2017; 8: 46090-46103.
- 14) DING J, XIE M, LIU X, ZHU Y, LIU X, WANG L, WANG K. Long non-coding RNA HOXA-AS2 represses P21 expression and cell proliferation by binding to ZEB2, LncRNA in lung cancer. *Oncogene* 2017; 6: e288.
- 15) WANG J, LIU S, LUO L. Knockdown of long non-coding RNA SNHG1 inhibits the proliferation and cellular invasion of osteosarcoma cells by sponging miR-153. *Cancer Res* 2018; 26: 665-673.
- 16) LIU X, XIA T. Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis. *Int J Oncol* 2017; 51: 1460-1470.
- 17) SONG J, WU X, LI F, LI M, SUN Y, WANG Y, WANG C, LIU K, JIA X, LI B, MA X. Long non-coding RNA SNHG1 promotes glycolysis and tumor progression by targeting miR-497/HK2 axis in osteosarcoma. *Biochem Biophys Res Commun* 2017; 490: 217-224.
- 18) LIU J, CAO L, WU J, WANG Q. Long non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma. *Int J Oncol* 2018; 52: 77-88.
- 19) WU G, YU W, ZHANG M, YIN R, WU Y, LIU Q. MicroRNA-145-3p suppresses proliferation and promotes apoptosis and autophagy of osteosarcoma cell by targeting HDAC4. *Artif Cells Nanomed Biotechnol* 2018; 46(Suppl 2): 579-586.
- 20) MATSUSHITA R, YOSHINO H, ENOKIDA H, GOTO Y, MIYAMOTO K, YONEMORI M, INOGUCHI S, NAKAGAWA M, SEKI N. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness. *Oncotarget* 2016; 7: 28460-28487.
- 21) MO D, YANG D, XIAO X, SUN R, HUANG L, XU J. MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin. *Biotechnol Lett* 2017; 39: 701-710.
- 22) CHANG Y, YAN W, SUN C, LIU Q, WANG J, WANG M. MiR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells. *Oncol Lett* 2017; 14: 6923-6928.